Cancer Advisor | One Day MD

A comprehensive comparison of three antiparasitic drugs, their proposed anticancer mechanisms, human clinical evidence, the emerging triple combination (IFM), safety concerns and the potential for future drug repurposing. Evidence review updated: November 2026 Key message: Ivermectin, fenbendazole, and mebendazole have demonstrated biological activity in selected preclinical cancer models. However, none is an established cancer treatment, and all remain investigational. The triple combination of ivermectin, fenbendazole, and mebendazole (IFM) is likewise an investigational hypothesis, with no demonstrated clinical efficacy or validated evidence of synergistic activity. Introduction: Three antiparasitic drugs attracting attention in oncology Ivermectin, fenbendazole and mebendazole have attracted considerable attention in cancer research and online discussions about drug repurposing. All three are antiparasitic medications, but they belong to different pharmacological cat...

Abstract Background Pancreatic cancer remains one of the most lethal malignancies despite modern chemotherapy. Increasing public interest has emerged around repurposed antiparasitic drugs such as fenbendazole, mebendazole, and ivermectin. Objective To reorganise and analyse anecdotal pancreatic cancer case reports involving fenbendazole and ivermectin-based protocols in order to identify recurring response patterns and clinically relevant subgroups. Methods Publicly available anecdotal reports were reviewed qualitatively and reorganised according to biomarker response, metastatic pattern, chemotherapy use, histology, and adjunct metabolic therapies. Results Recurring themes included rapid CA19-9 decline, apparent liver metastasis responses, heavy reliance on combination chemotherapy, delayed-response patterns, and extensive use of nutraceutical adjuncts. Most reported responders received multi-modal therapy rather than antiparasitic monotherapy. Conclusion The reports are highly vulner...